The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy (Q28646882)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy |
scientific article |
Statements
The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy (English)
Xiaolong Tang
Qingguo Li
Yongqiang Zhu
Donghui Zheng
Wenxuan Ni
Jia Wei
Yubao Xue
Ke Chen
Wei Hou
Chao Zhang
Xiaojun Feng
1 reference